Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 2/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.46 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 5/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22050814 | 0.90 | CLK1 (0.52) | CLK1DYRK1ASTING1AAK1BRAF | |
| SCHEMBL22050239 | 0.87 | STING1 (0.54) | STING1AAK1IGF1RRIPK1 | |
| SCHEMBL30021859 | 0.83 | TAAR1 (0.56) | CLK1DYRK1AAAK1RIPK1 | |
| SCHEMBL21988041 | 0.83 | STING1 (0.59) | CLK1DYRK1ASTING1AAK1BRAF | |
| SCHEMBL22049591 | 0.82 | STING1 (0.46) | CLK1DYRK1ASTING1AAK1BRAF | |
| SCHEMBL22049571 | 0.82 | STING1 (0.58) | CLK1DYRK1ASTING1AAK1BRAF | |
| SCHEMBL22049477 | 0.82 | AAK1 (0.46) | CLK1DYRK1ASTING1AAK1CDK8 | |
| SCHEMBL22049594 | 0.82 | STING1 (0.51) | CLK1DYRK1ASTING1AAK1BRAF | |
| SCHEMBL21988107 | 0.81 | AAK1 (0.46) | CLK1DYRK1AAAK1KDRGSK3A | |
| SCHEMBL22049735 | 0.81 | DYRK1A (0.49) | CLK1DYRK1ASTING1AAK1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | NOVARTIS PHARMA AG (CH) | 2023-04-06 | — | — | US | disclosed |
| WO-2020257621-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20200172534-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172534-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | CLK1 1338/4885DYRK1A 4056/4885STING1 1/4885 |
| US-20230106899-A1 | METHODS OF TREATING CANCER | STING1, CGAS, TBK1 | CLK1 615/4885DYRK1A 2647/4885STING1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.